{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T01:29:22Z","timestamp":1789349362553,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.vaccine.2007.01.016","type":"journal-article","created":{"date-parts":[[2007,1,19]],"date-time":"2007-01-19T07:19:09Z","timestamp":1169191149000},"page":"3007-3013","source":"Crossref","is-referenced-by-count":96,"title":["Human papilloma virus (HPV) prophylactic vaccination: Challenges for public health and implications for screening"],"prefix":"10.1016","volume":"25","author":[{"given":"M.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Jasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fiander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2007.01.016_bib1","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jcp.55.4.244","article-title":"The causal relation between human papillomavirus and cervical cancer","volume":"55","author":"Bosch","year":"2002","journal-title":"J Clin Pathol"},{"issue":"5","key":"10.1016\/j.vaccine.2007.01.016_bib2","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase 11 efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2007.01.016_bib3","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"issue":"9430","key":"10.1016\/j.vaccine.2007.01.016_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(04)16674-9","article-title":"The cervical cancer epidemic that screening prevented in the UK","volume":"364","author":"Peto","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2007.01.016_bib5","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-132-10-200005160-00009","article-title":"Accuracy of the Papanincolaou test in screening for and follow up of cervical cytologic abnormalities: a systematic review","volume":"132","author":"Nanda","year":"2000","journal-title":"Ann Int Med"},{"key":"10.1016\/j.vaccine.2007.01.016_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.bjc.6600974","article-title":"Benefit of cervical screening at different ages: evidence from UK audit of screening histories","volume":"89","author":"Sasieni","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2007.01.016_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/01.AOG.0000115510.81613.f0","article-title":"Cervical screening in the National Breast and Cervical Cancer Early Detection Program 1995\u2013201","volume":"103","author":"Benard","year":"2004","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2007.01.016_bib8","unstructured":"Office of National Statistics Cervical Cancer Screening Programme. England 2004\u20132005."},{"key":"10.1016\/j.vaccine.2007.01.016_bib9","unstructured":"Cervical Screening Wales Annual Report 2005."},{"key":"10.1016\/j.vaccine.2007.01.016_bib10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/sj.bjc.6603086","article-title":"Psychological effects of low grade abnormal cervical smear test result: anxiety and associated factors","volume":"94","author":"Gray","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2007.01.016_bib11","unstructured":"NHS Health & Social Care Information Centre. Community Health Services Statistics website: http:\/\/www.cnhs.uk\/."},{"key":"10.1016\/j.vaccine.2007.01.016_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/1097-0142(20010225)93:1<8::AID-CNCR9001>3.0.CO;2-K","article-title":"Papanicololaou smear sensitivity for the detection of adenocarcinoma of the cervix: a study of 49 cases","volume":"93","author":"Krane","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2007.01.016_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/1097-0339(200008)23:2<127::AID-DC13>3.0.CO;2-I","article-title":"Can glandular lesions be diagnosed in pap smear cytology?","volume":"23","author":"Raab","year":"2000","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.vaccine.2007.01.016_bib14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/ijc.20678","article-title":"Cervical cancer in the Netherlands 1989\u20131998: decrease of squamous carcinoma in older women, increase of adenocarcinoma in younger women","volume":"1134","author":"Bulk","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2007.01.016_bib15","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2007.01.016_bib16","first-page":"469","article-title":"Improving vaccine performance with adjuvants","volume":"30","author":"Vogel","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2007.01.016_bib17","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1056\/NEJMoa011915","article-title":"Glycoprotein-d-adjuvant vaccine to prevent genital herpes","volume":"347","author":"Stanberry","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2007.01.016_bib18","series-title":"6th international multidisciplinary congress of the European research organization on genital infection and neoplasia (EUROGIN)","article-title":"Review of the initial phase 3 clinical data for the quadrivalent human papilloma virus vaccine","author":"Munoz","year":"2006"},{"key":"10.1016\/j.vaccine.2007.01.016_bib19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.vaccine.2006.06.014","article-title":"Current findings from prophylactic HPV vaccine trials","volume":"24S3","author":"Koutsky","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.016_bib20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.20244","article-title":"Against which human papillomavirus types shall we vaccinate and screen? The international perspective","volume":"111","author":"Munoz","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2007.01.016_bib21","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0140-6736(05)67069-9","article-title":"Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis","volume":"366","author":"Clifford","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2007.01.016_bib22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1158\/1055-9965.EPI-04-0812","article-title":"Human papilloma virus genotype distribution in low grade lesions: comparison by geographic region and with cervical cancer","volume":"14","author":"Clifford","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2007.01.016_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1128\/JVI.67.1.315-322.1993","article-title":"Self assembly of human papillomavirus type 1 capsids by expression of the LI protein alone or by coexpression of the LI and L2 capsid proteins","volume":"67","author":"Hagensee","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2007.01.016_bib24","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papilloma virus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2007.01.016_bib25","series-title":"2006 poster P-200 23rd international papilloma conference and clinical workshop","article-title":"Estimating the long term impact of a prophylactic human papilloma virus (HPV) 16\/18 vaccine on the burden of cervical disease in the UK","author":"Kohli","year":"2006"},{"key":"10.1016\/j.vaccine.2007.01.016_bib26","first-page":"S3\/42","article-title":"Updating natural history of HPV and anogenital cancer","volume":"24S3","author":"Moscicki","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.016_bib27","first-page":"S3\/122","article-title":"HPV vaccine introduction in industrialised countries","volume":"24S3","author":"Wright","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2007.01.016_bib28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.AOG.0000192397.41191.fb","article-title":"Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomised controlled trial","volume":"107","author":"Mao","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2007.01.016_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.vaccine.2006.06.017","article-title":"Psychosocial aspects of vaccine acceptability","volume":"24S3","author":"Zimet","year":"2006","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2007.01.016_bib30","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1016\/j.vaccine.2006.01.048","article-title":"Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes","volume":"24","author":"Brabin","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2007.01.016_bib31","first-page":"318","article-title":"Universal hepatitis B vaccination of UK adolescents a feasibility acceptability study","volume":"5","author":"Bramley","year":"2002","journal-title":"Commun Dis Public Health"},{"key":"10.1016\/j.vaccine.2007.01.016_bib32","first-page":"S3\/171","article-title":"Issues in planning cervical screening in the era of HPV vaccination","volume":"24S3","author":"Franco","year":"2006","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X07000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T16:23:43Z","timestamp":1587313423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X07000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":32,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0264410X07000369"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2007.01.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}